Inotiv, Inc.

Equities

NOTV

US45783Q1004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:13:34 2024-07-16 pm EDT			5-day change	1st Jan Change
2.345 ^USD	+10.61%		+28.65%	-37.60%

Jun. 04	Inotiv, Inc. Enters into A Fifth Amendment to the Credit Agreement	CI
Jun. 03	Inotiv to Pay $35 Million for Canine-Breeding Facility Violations	DJ

Bioanalytical Systems, Inc. Elects Robert Leasure as President, Chief Executive Officer and as a Director

January 16, 2019 at 08:33 am EST

Bioanalytical Systems, Inc. announced the election of Robert Leasure, Jr., as President and Chief Executive Officer and as a director of the company, effective as of January 12, 2019. Robert Leasure, Jr., serves as the managing partner and president of LS Associates LLC.

Latest news about Inotiv, Inc.

Inotiv, Inc. Enters into A Fifth Amendment to the Credit Agreement	Jun. 04	CI
Inotiv to Pay $35 Million for Canine-Breeding Facility Violations	Jun. 03	DJ
Inotiv, Inc. Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility	Jun. 03	CI
US breeder Envigo pleads guilty for mistreating beagles, gets largest-ever fine	Jun. 03	RE
North American Morning Briefing : The "Everything -2-	May. 17	DJ
Craig Hallum Adjusts Inotiv Price Target to $10 From $25, Maintains Buy Rating	May. 16	MT
Inotiv, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15	CI
Earnings Flash (NOTV) INOTIV Posts Q2 Revenue $119M, vs. Street Est of $133.1M	May. 15	MT
Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024	May. 15	CI
Wall Street Set to Open Flat Tuesday as Key Inflation Gauge Rises More Than Expected	May. 14	MT
Top Premarket Decliners	May. 14	MT
Investors Await Key Inflation Data as US Futures Tread Water in Premarket Session	May. 14	MT
Jefferies Downgrades Inotiv to Hold From Buy, Price Target is $3.75	May. 14	MT
Inotiv Delays Release of Fiscal Q2 Results	May. 10	MT
Inotiv, Inc. Elects Michael J. Harrington as Class III Member of the Board	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Feb. 12	DJ
Jefferies Upgrades Inotiv to Buy Rating From Hold, Adjusts Price Target to $11.50 From $3	Feb. 09	MT
Inotiv, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Transcript : Inotiv, Inc., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (NOTV) INOTIV Reports Q1 Revenue $135.5M, vs. Street Est of $132.9M	Feb. 07	MT
Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024	Feb. 07	CI
An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc..	Feb. 06	CI
Jefferies Adjusts Inotiv Price Target to $3 From $7.25, Maintains Hold Rating	Dec. 13	MT
Craig-Hallum Adjusts Price Target on Inotiv to $25 From $34, Maintains Buy Rating	Dec. 12	MT
Inotiv Q4 Loss Narrows, Revenue Falls; Issues Fiscal 2024 Guidance -- Shares Rise After Hours	Dec. 11	MT

Chart Inotiv, Inc.

Duration

Period

More charts

Company Profile

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Inotiv, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.12 USD

Average target price

4.667 USD

Spread / Average Target

+120.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOTIV, INC.	-37.60%	55.06M
MODERNA, INC.	+25.35%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.28%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.36%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.83%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.84%	14.52B
MEDPACE HOLDINGS, INC.	+47.45%	13.74B
BIO-TECHNE CORPORATION	+3.13%	12.17B

Other Biotechnology & Medical Research